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Pulmonary arterial hypertension (PAH) is now
a well-known complication of HIV infection [1].
Its clinical and pathological features resemble
those of primary pulmonary hypertension (PPH).
The incidence of HIV-associated PAH is about
0.5% [1, 2]. Thus, in comparison with the inci-
dence of PPH in the normal population (1–2 per
million), HIV-infected subjects have a 2500-fold
risk of PAH [1–3]. More than 60% of the cases are
males, and the mean age at the time of diagnosis is
33 years [4, 5]. Half of the patients have acquired
the HIV infection through intravenous drug use,
30% through sexual contacts and 20% from blood
products. The mean CD4 count is 300 cell per µL
with a range from 0–900 [1, 4, 5]. Thus, PAH af-
fects all stages of HIV infection, and only one third
of the cases have AIDS. Patients with HIV-asso-
ciated PAH have significantly decreased survival 
in comparison with a matched population of HIV-
infected patients without PAH [2]. Median survival
is about one year [2, 5], and most patients die
within three years [5]. Treatment consists of anti-
coagulation and vasodilators. The latter elicit
some haemodynamic response in about half of
patients [6]. The pathogenesis of HIV-associated
PAH is still unknown. While it has never been con-
vincingly shown that the virus itself has a direct im-
pact on the pulmonary vasculature, we have been
able to demonstrate that the course of pulmonary
hypertension tended to improve in our patients
treated with zidovudine or didanosine [2]. On the
other hand, an accelerated course of the disease has
been reported in two patients given highly active
antiretroviral treatment [7].
In a 37-year-old patient HIV infection was di-
agnosed in June 1986. Eight years later the patient
complained of increasing shortness of breath and
occasional syncopes on exertion. He developed
peripheral oedema and ascites. Echocardiography
revealed severe pulmonary hypertension. Right
ventricular systolic pressure (RVSP) was 77 
mm Hg. There was no evidence of left ventricular
dysfunction, valvular heart disease, thrombo-
embolic disease or obstructive or restrictive lung
disease, nor were there other known causes or risk
factors of pulmonary hypertension. HIV-asso-
ciated pulmonary arterial hypertension was diag-
nosed. Oral anticoagulation and zidovudine were
begun, but RVSP rose to 96 mm Hg. After the
introduction of lamivudine, and later stavudine
and nelfinavir, HIV-RNA copies decreased from
133 400 to below 50 copies per mL. Six years after
the diagnosis of HIV-associated pulmonary arte-
rial hypertension RVSP had continually fallen to
49 mm Hg and the grossly enlarged right heart
dimensions had nearly normalised without vaso-
dilator treatment. The patient remains in excellent
health and his sole complaint is of mild dyspnoea
on exertion.
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Summary
Introduction
Case report
In a 37-year-old intravenous drug user HIV infection
was diagnosed in June 1986. After entering a methadone
programme he regularly consumed intravenous cocaine
until mid-1995. For the next two years he consumed
cocaine fewer than 6 times a year, and since summer 1997
he has been totally abstinent. In December 1991 echocar-
diography for suspected right-heart endocarditis was
completely normal. Right ventricular systolic pressure
(RVSP) was 27 mm Hg (normal ≤30 mm Hg) over right
atrial pressure (RAP). Blood cultures were negative. The
CD4 count was 840 cells per µL (figure 1). At that time
the patient exhibited no cardiopulmonary symptoms or
signs.
In September 1994 he complained of increasing
shortness of breath and occasional syncope on exertion.
He developed peripheral oedema and ascites. A further
echocardiogram revealed severe pulmonary hypertension.
RVSP was 77 mm Hg over RAP (figure 1). There was no
evidence of left ventricular dysfunction, valvular heart dis-
ease, thromboembolic disease or obstructive or restrictive
lung disease, nor were there other known causes or risk
factors of pulmonary hypertension [8]. HIV-associated
pulmonary arterial hypertension was diagnosed and oral
anticoagulation and antiretroviral treatment with zidovu-
dine 250 mg twice daily was begun. The CD4 count in-
creased from 430 to 550 cells per µL, but severe exertional
dyspnoea persisted. One year later an echocardiogram
showed even higher RVSP of 96 mmHg over RAP. Right
atrial and ventricular dimensions were grossly enlarged:
the short right ventricular axis was 5.8 cm (normal ≤4.0
cm), and the long and short right atrial axes were 6.8 cm
(normal ≤5.0 cm) and 6.3 cm (normal ≤4.1 cm) respec-
tively (figure 1).
Six months later RVSP was still 90 mm Hg over RAP.
At that time CD4 counts had decreased to 290 cells per
µL, and the viral load, measured for the first time, was
133 400 HIV-RNA copies per mL. Lamivudine 150 mg
twice daily was added, and the viral load decreased to 1580
copies per mL. Surprisingly, a further echocardiogram
showed decreased RVSP of 54 mm Hg over RAP and near-
normalisation of the right atrial and ventricular diameters
without vasodilator treatment. Ascites and peripheral
oedema had disappeared, and the patient complained only
of mild dyspnoea on exertion (NYHA class II–III). One
year later, RVSP had again risen, to 71 mm Hg over RAP,
as had viral load (6860 copies per mL). After replacement
of zidovudine by stavudine 40 mg twice daily, and intro-
duction of nelfinavir 1250 mg twice daily, the viral load
had fallen below the detection limit 6 months later. Con-
currently, RVSP had again decreased to 63 mm Hg over
RAP.
After another rise in RVSP to 74 mm Hg over RAP
and transient reappearance of syncopes, ascites and pe-
ripheral oedema, there was a steady echocardiographic
and clinical improvement. In January 2001 RVSP was only
49 mm Hg over RAP. Only the short right atrial axis was
slightly enlarged (5.3 cm), while the other right heart
dimensions had normalised. The patient remains in ex-
cellent health and his only complaint is of mild dyspnoea
on exertion (NYHA class II) 6 years after the diagnosis of
HIV-associated pulmonary arterial hypertension.
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Figure 1
HIV-associated
pulmonary arterial
hypertension: clinical
course during anti-
retroviral therapy.
RVSP = right ventric-
ular systolic pressure
over right atrial
pressure; RV = right
ventricular axis; 
RA = right atrial axis;
IVDA/C = intravenous
cocaine abuse. 
Discussion
The clinical course of this patient with HIV-
associated pulmonary arterial hypertension sug-
gests a favourable effect of antiretroviral combina-
tion therapy on the evolution of this disease, par-
ticularly after successful suppression of HIV viral
load. The potential relationship between HIV
RNA load and pulmonary hypertension is further
suggested by the second improvement in the pa-
tient’s RVSP after the introduction of stavudine
and nelfinavir. The six years-plus survival in this
case is exceptional in that most patients with HIV-
associated PAH die within three years of diagnosis
[2, 5]. Even more unusual is the spontaneous
regression of pulmonary hypertension without
vasodilator treatment. To date this has been de-
scribed in only two cases in the literature. In both
of them pulmonary hypertension developed dur-
ing infancy and haemodynamic improvement oc-
curred in early adulthood [9, 10]. 
Although the patient’s cocaine use may to
some extent have contributed to the course of
PAH, the second WHO conference did not regard
cocaine as a very probable risk factor for PAH [11].
The occurrence of PPH in HIV-negative cocaine
users is highly unusual: there are only nine re-
ported cases in the literature, in which pulmonary
hypertension was usually mild (RVSP 30–44 mm
Hg over RAP) [12] and transient [13]. Thus, in ac-
cordance with our findings in a recently published
cohort study [2], the favourable clinical course of
HIV-associated PPH suggests an important role
for antiretroviral combination therapy in this dis-
order. Even if the aetiology of HIV-associated
PAH is still unknown, HIV infection probably acts
as a trigger mechanism for the rise in pulmonary
vascular resistance and the treatment-induced de-
crease in the HIV viral load may well exercise a
beneficial effect on this postulated interaction.
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